Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
193.62
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AbbVie
< Previous
1
2
3
4
5
6
7
Next >
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
February 27, 2024
From
Healis Therapeutics
Via
GlobeNewswire
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Friday Morning
February 16, 2024
Via
Investor Brand Network
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning
February 07, 2024
Via
Investor Brand Network
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
AbbVie turns a corner; patent cliff fears were overblown
February 02, 2024
AbbVie's patent cliff is already a thing of the past with Skyrizi and Rinvoq outperforming and other assets also strong. Dividends are safe, growth is back.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
Get News
Exposures
Product Safety
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning
January 24, 2024
Via
Investor Brand Network
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
January 02, 2024
Via
Investor Brand Network
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024
From
FN Media Group LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
January 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
December 22, 2023
Via
Investor Brand Network
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...
Via
TheNewswire.com
Exposures
Product Safety
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
January 04, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
December 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
AbbVie continues shopping spree with biotech buyout
December 12, 2023
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.
Via
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
December 11, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
December 04, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
October 30, 2023
Via
Investor Brand Network
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
Via
MarketBeat
These are the top sectors for blue chip growth in 2024
November 29, 2023
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains.
Via
MarketBeat
Topics
Economy
Intellectual Property
Exposures
COVID-19
Intellectual Property
Interest Rates
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Via
MarketBeat
Guidance leads the market for these stocks; 1 raises, 1 lowers
November 07, 2023
Guidance is a driving force for equity markets and can lead stock prices higher or lower, catalyze significant moves, and alter analysts' outlook
Via
MarketBeat
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
J&J stock down as business unit mulls talc-related bankruptcy
October 31, 2023
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements.
Via
MarketBeat
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Legal
High-yield, deep-value AbbVie fell off the patent cliff and lived
October 27, 2023
AbbVie's deep value and high yield attract income investors, and the patent cliff worry lessens daily.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend
September 26, 2023
The Clorox Company's 44% two-year plunge has created an opportunity to own a defensive stock with a shiny 3.6% dividend.
Via
MarketBeat
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.